At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.
Type
Subsidiary
HQ
Durham, US
Founded
1974
Patheon was founded in 1974 and is headquartered in Durham, US

Patheon Office Locations

Patheon has an office in Durham
Durham, US (HQ)
300 4815 Emperor Blvd

Patheon Financials and Metrics

Summary Metrics

Founding Date

1974
Patheon is a subsidiary of Thermo Fisher Scientific

Patheon Financials

Patheon's revenue was reported to be $1 b in FY, 2013
USDFY, 2013

Revenue

1 b

Cost of goods sold

774 m

Gross profit

249.1 m

Gross profit Margin, %

24%
USDFY, 2013

Cash

61.6 m

Accounts Receivable

191.3 m

Inventories

137.8 m

Current Assets

415.7 m
USDFY, 2013

Depreciation and Amortization

48.4 m

Cash From Operating Activities

13 m

Cash From Financing Activities

306.9 m

Interest Paid

42.1 m
Show all financial metrics

Patheon Median Salaries

Source: 16 public H-1B filings from Patheon

Patheon's Web-traffic and Trends

Patheon Online and Social Media Presence

Patheon News and Updates

Pharmaceutical Solid Dosage Contract Manufacturing Market to witness steady increase by 2024

The major factors that are driving the pharmaceutical solid dosage contract manufacturing market include lower and more flexible manufacturing, reduced net costs, streamlined development, and availability of the higher quality product. Posted via Industry Today. Follow us on Twitter @IndustryToday

Pharmaceutical Solid Dosage Contract Manufacturing Market: Industry Latest Trends & Global Outlook 2016-2024

The major factors that are driving the pharmaceutical solid dosage contract manufacturing market include lower and more flexible manufacturing, reduced net costs, streamlined development, and availability of the higher quality product. Posted via Industry Today. Follow us on Twitter @IndustryToday

Vicarius Pharma lands $21.8 mln

Switzerland-based Vicarius Pharma AG, which provides U.S.-based biopharmaceutical companies a "novel approach" to commercializing assets in European markets, has raised $21.8 million in funding. James Mullen, CEO of Patheon and former CEO of Biogen, was the lead investor.

BRIEF-Patheon reports Q2 adjusted earnings of $0.20/shr from continuing operations

* Q2 adjusted earnings per share $0.20 from continuing operations

Patheon, built on a series of acquisitions, is snapped up by Thermo Fisher in $7.2B deal

Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a deal valued at $7.2 billion.

Thermo Fisher to buy drug ingredients maker Patheon for $5.2 billion

(Reuters) - Thermo Fisher Scientific Inc said on Monday it would buy Dutch drug ingredients maker Patheon NV , as it looks to become a one-stop shop for contract drug development and manufacturing.

Patheon Company Life and Culture

You may also be interested in